<DOC>
	<DOCNO>NCT01825954</DOCNO>
	<brief_summary>The purpose study test safety efficacy noninvasive cortical electrostimulation therapy know `` Reduced Impedance Noninvasive Cortical Electrostimulation '' ( RINCE ) management fibromyalgia . Patients meet 1990 American College Rheumatology criterion fibromyalgia receive 24 RINCE treatment deliver medical device call `` NeuroPoint '' . Approximately 45 fibromyalgia patient randomize one three study group . One group receive sham treatment , mean receive treatment , remain two group receive different amount RINCE therapy . The study 's primary outcome measure patient 's change baseline self-reported 24-hour average pain intensity . The study 's hypothesis difference treatment group primary outcome measure .</brief_summary>
	<brief_title>Prospective Evaluation RINCE Reduce Fibromyalgia Effects - St. Joseph Mercy Oakland</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Patient must provide write informed consent privacy authorization prior participation study . Patient must ability read and/or follow write oral instruction , abide study restriction , agree return require assessment . Patient male female , 2265 year age ( inclusive ) time consent . Patient must confirm diagnosis fibromyalgia meeting ACR 1990 classification criterion fibromyalgia . Patients must 24hour recall pain intensity score screen baseline visit 40 90 inclusive 100 mm VAS scale . Female patient childbearing potential must willing use acceptable method birth control duration study participation . Acceptable birth control include vasectomized partner , contraceptive ( oral , parenteral , transdermal ) , intrauterine device , double barrier method include condom , sponge , diaphragm , vaginal ring spermicidal jelly cream . Patients consider childbearing potential must surgically sterile ( total hysterectomy , bilateral salpingooophorectomy , tubal ligation ) great one year postmenopausal , define complete cessation menstruation least one year . Patients must willing refrain exclude therapy duration study . In opinion Investigator , patient willing able comply protocolspecified requirement . Patient current significant psychological psychiatric disorder ( e.g. , severe , unstable poorly control depression , severe anxiety obsessivecompulsive disorder ; history suicide attempt within precede 5 year suicidal ideation within precede 6 month ; history bipolar disorder , schizophrenia , schizoaffective psychotic disorder ) . Patient score 2 3 item 9 BDI , , base investigator 's judgment , patient risk suicidal ideation behavior . Patient currently use prohibit medication treatment ( see Prohibited Concomitant Therapy section protocol ) include FDAapproved fibromyalgia treatment , centrally active analgesic , stimulant , anesthetic patch , CPAP and/or TENS therapy . Patient active diagnosis treat chronic infection chronic condition lupus , rheumatoid arthritis , Parkinson 's disease , multiple sclerosis , hepatitis , polio , seizure , cancer ( basal squamous cell skin cancer ) . Patient chronic pain condition fibromyalgia , Investigator 's opinion , would interfere assessment fibromyalgia ( e.g. , rheumatoid arthritis , post herpetic neuralgia , pain associate diabetic neuropathy , severe pain due degenerative joint disease , etc . ) Patient history seizure disorder , dementia epilepsy anytime life except pediatric febrile seizure . Female patient pregnant , plan pregnancy , breastfeed . Patient disease medical condition , opinion investigator , would interfere evaluation study device efficacy safety , would compromise patient 's ability participate complete study . Patient history cranial electrical stimulation device use , electroconvulsive therapy . Patient metal implant , stent , aneurysm clip , shunt , pacemaker , defibrillator neurostimulators . Longbone implant exclude . Any anticipated need surgery might confound result interfere patient 's ability comply protocol . Myocardial infarction precede 12 month , uncontrolled hypertension , active cardiac disease ( American Heart Association Functional Class 2 , 3 4 Objective Class C D ) , clinically significant cardiac rhythm conduction abnormality , anticipation bypass cardiac surgery within next 12 month . Current systemic infection ( e.g. , HIV , hepatitis ) . Patients receive systemic corticosteroid ( &gt; 5 mg prednisone equivalent per day ) . Patients receive regular frequent opioids , opiates narcotic . Pending current litigation disability claim ( include Workman 's Compensation ) . Patients currently receive disability benefit require medical monitor approval casebycase basis . Patient history alcohol and/or drug abuse . Patient participate investigational study within 30 day prior Screening visit currently participate another clinical trial . Patient receive prior experimental treatment therapy , opinion medical monitor , would compromise patient 's ability participate study . Patient staff member relative staff member either investigative site Cerephex Corporation .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Pain</keyword>
	<keyword>Brain</keyword>
	<keyword>Stimulation</keyword>
	<keyword>Device</keyword>
</DOC>